US4379141A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for recovering myeloperoxidase and pharmaceutical composition containing myeloperoxidase as major constituent
Assignee: Tanabe Pharma Corp
•
Filing: 1981-08-28
•
Granted: 1983-04-05
•
Expires: 2001-08-28
Abstract
Abstract Myeloperoxidase can be separated and recovered from a supernatant liquid of an aqueous dispersion of a disintegration product of human myelogenous leukocytes, which dispersion has been admixed with at least one member selected from the group consisting of manganese salts and protamine sulfate. The recovered myeloperoxidase in combination with an alkali metal halide can be used as a pharmaceutical composition effective against microorganisms deficient or diminished in catalase synthesizing activity.
Inventors
- 👤 Eichi Hasegawa
- 👤 Takashi Kobayashi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 16:03
CPC Classifications
B; B65; B65B; B65B5/00; B65B5/02; Y; Y10; Y10S; Y10S435/00; Y10S435/814; Y10S435/816
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
47 words
A pharmaceutical composition effective against tubercle bacillus resistant to isonicotinic acid hydrazide deficient or diminished in catalase synthesizing activity, consisting essentially of 5 to 0.05 m moles of a pharmacologically acceptable alkali metal halide for 100 to 0.05 units of a myeloperoxidase originated from human myelogenous leukocytes.
Claim 2
Dependent Claim
47 words
A pharmaceutical composition effective against tubercle bacillus resistant to isonicotinic acid hydrazide deficient or diminished in catalase synthesizing activity, consisting essentially of 5 to 0.05 m moles of a pharmacologically acceptable alkali metal halide for 100 to 0.05 units of a myeloperoxidase originated from human myelogenous leukocytes.
Claim 3
Dependent Claim
21 words
A pharmaceutical composition according to claim 1, wherein the alkali metal halide is a chloride or iodide of potassium or sodium.
Claim 4
Dependent Claim
15 words
A pharmaceutical composition according to claim 1, wherein the alkali metal is sodium or potassium.
Claim 5
Dependent Claim
41 words
A method of combatting pathogenic tubercle bacillus resistant to isonicotinic acid hydrazide deficient or diminished in catalase synthesizing activity consisting essentially of administering to a living animal infected with such tubercle bacillus an effective amount of the composition of claim 1.
Claim 6
Dependent Claim
51 words
A method according to claim 4 wherein the myeloperoxidase has been prepared by admixing an aqueous suspension of a disintegration product of human myelogenous leukocytes with at least one member selected from the group consisting of manganese salts and protamine sulfate and then separating and recovering myeloperoxidase from the supernatant liquor.
Claim 7
Dependent Claim
52 words
A pharmaceutical composition according to claim 1 wherein the myeloperoxidase has been prepared by admixing an aqueous suspension of a disintegration product of human myelogenous leukocytes with at least one member selected from the group consisting of manganese salts and protamine sulfate and then separating and recovering myeloperoxidase from the supernatant liquor.
Claim 8
Dependent Claim
15 words
A pharmaceutical composition according to claim 6 consisting of said myeloperoxidase and alkali metal halide.
Claim 9
Dependent Claim
15 words
A pharmaceutical composition according to claim 3 consisting of said myeloperoxidase and alkali metal halide.
Claim 10
Dependent Claim
15 words
A pharmaceutical composition according to claim 2 consisting of said myeloperoxidase and alkali metal halide.
Claim 11
Dependent Claim
15 words
A pharmaceutical composition according to claim 1 consisting of said myeloperoxidase and alkali metal halide.
Claim 12
Dependent Claim
20 words
A method according to claim 5 wherein there is employed a composition consisting of said myeloperoxidase and alkali metal halide.
Claim 13
Dependent Claim
20 words
A method according to claim 4 wherein there is employed a composition consisting of said myeloperoxidase and alkali metal halide.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-04-04 | 1986-10-04 | 1987-04-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-04-04 | 1990-10-04 | 1991-04-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-04-04 | 1994-10-04 | 1995-04-05 | $7700.00 | Window Closed / Lapsed |